Products for Research Use Only

Palbociclib-d4 (hydrochloride)

CAT: 0804-HY-50767S1-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50767S1-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Palbociclib-d4 (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
Product Name Alternative
PD 0332991-d4 (hydrochloride)
UNSPSC
12352005
Target
CDK; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
O=C1C(C(C)=O)=C(C2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(N5CC([2H])([2H])NC([2H])([2H])C5)C=N4)C.Cl
Molecular Formula
C24H26D4ClN7O2
Molecular Weight
488.02
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38.|[3]Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun, 2011, 413 (1), 62-68.|[4]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548 (7668) :471-475.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported